Skip to main content
SpringerLink
Log in

FDA approves YOSPRALA for patients at risk of gastric ulcers

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Aralez Pharmaceuticals Inc.. Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers. Media Release : 15 Sep 2016. Available from: URL: http://www.aralez.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

FDA approves YOSPRALA for patients at risk of gastric ulcers. Reactions Weekly 1621, 8 (2016). https://doi.org/10.1007/s40278-016-21561-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-21561-2

Search

Navigation